ADMA Biologics, Inc. (ADMA) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
Analysis Summary
ADMA Biologics, Inc. reported revenue of $510.2M in the most recent fiscal year, growing at a 5-year CAGR of 64.6%.
Trailing-twelve-month margins: gross margin 64.7%, operating margin 42.3%, net margin 33.0%.
At the current price of $8.90, ADMA trades at a P/E of 12.55 and an ROE of 30.78%. Market capitalisation stands at $2.1B.
Balance sheet quality for ADMA: current ratio of 6.7, net cash position of $7.7M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is below average: free cash flow of $27.8M represents 19% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $8.90 |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 12.55 |
| Price / Book | 5.05 |
| EV / EBITDA | 21.93 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 30.78% |
| Return on Invested Capital | 27.57% |
| Return on Assets | 23.54% |
| Gross Margin | 64.71% |
| Operating Margin | 42.26% |
| Net Margin | 32.98% |
Financial Health
| Debt / Equity | 0.50 |
| Current Ratio | 6.97 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 19.98 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ADMA | ADMA Biologics, Inc. | $2.1B | 12.55 | 5.05 | 30.8% |
| BLTE | Belite Bio, Inc | $6.8B | 8.75 | -10.1% | |
| PRAX | Praxis Precision Medicines, Inc. | $8.6B | 6.34 | ||
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | -410.2% | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| LGND | Ligand Pharmaceuticals Incorporated | $5.7B | 27.49 | 5.71 | |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.8B | 12.10 | 3.57 | 32.4% |
| DYN | Dyne Therapeutics, Inc. | $3.4B | 4.20 | -64.3% |
Price Performance
| 1 month | -6.71% |
| 3 months | +7.10% |
| Year-to-date | -51.21% |
| 1 year | -42.80% |
| 3 years | +144.51% |
| 5 years | +589.92% |
52-Week Range
| 52-week High | $20.46 |
| 52-week Low | $7.21 |
| Avg Volume (90d) | 3.1M |
Related companies: ACAD · BLTE · CRNX · DYN · LGND · MIRM · PRAX
Explore sector: Healthcare · Biotechnology
More sections of ADMA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks